A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

• Kada Akiko

• Fukano Reiji

• Mori Tetsuya

• Kamei Michi

• Tanaka Fumiko

• Ueyama Junichi

• Sekimizu Masahiro

• Osumi Tomoo

• Mori Takeshi

• Koga Yuhki

• Ohki Kentaro

• Fujita Naoto

• Mitsui Tetsuo

• Saito Akiko M.

• Hashimoto Hiroya

• Kobayashi Ryoji

抄録

No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

収録刊行物

• Acta Medica Okayama

  Acta Medica Okayama 74 (1), 89-94, 2020-02

  Okayama University Medical School

キーワード

• anaplastic large-cell lymphoma
• relapsed/refractory
• fludarabine
• melphalan
• total body irradiation

詳細情報

• CRID: 1390009224822672640
• NII論文ID: 120006795626
• NII書誌ID: AA00508441
• ISSN: 0386300X
• DOI: 10.18926/amo/57959
• Web Site: https://ousar.lib.okayama-u.ac.jp/57959
• 本文言語コード: en
• データソース種別:
  • JaLC
  • IRDB
  • CiNii Articles